Compare Amphastar Pharmaceuticals Inc (AMPH) vs Quanta Services Inc (PWR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Quanta Services (PWR) trades at $658.56, down 1.44% with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth has been robust, increasing from $17.1B in 2022 to $28.5B in 2025, though profit margins remain modest at 3.67%. Analyst sentiment remains overwhelmingly positive with 27 buy ratings and a consensus price target of $836.80, representing 27% upside potential.

PWR presents a compelling growth story driven by infrastructure spending and AI-related opportunities, with management projecting technology revenues to rise over 110% by 2030. However, the stock trades at premium valuations (P/E 90.34) and faces execution risks from aggressive capital expenditure plans. The bearish technical setup suggests near-term pressure, but strong institutional support and massive infrastructure backlog provide long-term catalysts.